Daratumumab monotherapy for relapsed AL amyloidosis: a single center retrospective analysis. [PDF]
Yi JH +11 more
europepmc +1 more source
Daratumumab Treatment in Severe Anti-NMDAR Encephalitis: Two Case Reports and Literature Review. [PDF]
Ammar N +7 more
europepmc +1 more source
Targeting CD38 in relapsed /refractory T-cell acute lymphoblastic leukemia/lymphoma: A systematic review of daratumumab-based therapy. [PDF]
Al-Mashdali AF +5 more
europepmc +1 more source
Anti-CD38 monoclonal antibodies in multiple myeloma and beyond: immunotherapeutic mechanisms, evidence maturity, and clinical positioning. [PDF]
Yu L, Li C, Guo D, Cui S.
europepmc +1 more source
Sustained Response After a Six-Week Course of Subcutaneous Daratumumab in Multi-Refractory Immune Thrombocytopenia. [PDF]
Güllü Koca T, Yanık AM.
europepmc +1 more source
Choroidal Leakage during Daratumumab Therapy: A Desensitization-Based Strategy for Treatment Continuation in Relapsed/Refractory Multiple Myeloma. [PDF]
Mastanzade M +5 more
europepmc +1 more source
Intravenous daratumumab-based regimens for light-chain amyloidosis with kidney involvement: a retrospective real-world comparative study. [PDF]
Lei X +9 more
europepmc +1 more source
T-Cell Redirecting Antibodies for the Treatment of Multiple Myeloma: Off-the-Shelf T-Cell Immunity. [PDF]
van de Donk NWCJ +7 more
europepmc +1 more source
Economic advantage of daratumumab, bortezomib, lenalidomide, and dexamethasone vs bortezomib, lenalidomide, and dexamethasone for transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma: A cost-per-responder evaluation. [PDF]
Gautam S +7 more
europepmc +1 more source
Multiple myeloma: an overview of drug therapies and supportive care. [PDF]
Hocking J.
europepmc +1 more source

